Used in targeted cancer therapy, particularly for treating solid tumors such as breast cancer and other malignancies expressing the LIV-1 antigen. This antibody binds specifically to LIV-1, a zinc transporter protein overexpressed in certain cancers, enabling the delivery of cytotoxic agents directly to tumor cells when conjugated to a drug. It serves as the targeting component in antibody-drug conjugates (ADCs), enhancing treatment precision while minimizing damage to healthy tissues. Clinical development focuses on improving response rates in metastatic and treatment-resistant cancers.